Use of genetics in the prediction of success in male pattern hair loss therapy and mechanistic studies. [PDF]
Front PharmacolTorres de Souza G +6 more
europepmc +1 more source
Body mass index as a potential confounder in dutasteride and fertility studies. [PDF]
Clin Exp Reprod MedAkbari AR, Alam B, Ageed A.
europepmc +1 more source
Association between insulin resistance and prostate volume: A 4-year analysis from the Reduction by Dutasteride of Prostate Cancer (REDUCE) Trial. [PDF]
BJUI CompassDaniels JP +6 more
europepmc +1 more source
A Randomized, Double-Blind, Placebo and Active Controlled Phase II Study to Evaluate the Safety and Efficacy of Novel Dutasteride Topical Solution (0.01%, 0.02%, and 0.05% w/v) in Male Subjects With Androgenetic Alopecia. [PDF]
CureusPanuganti VK +6 more
europepmc +1 more source
Efficacy and Safety of Low-Dose (0.2 mg) Dutasteride for Male Androgenic Alopecia: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase III Clinical Trial. [PDF]
Ann DermatolLee S +13 more
europepmc +1 more source
Efficacy of Skin Patting and Iontophoresis with Dutasteride Gel in Male and Menopausal Female Androgenetic Alopecia: A Pilot Study. [PDF]
Dermatol Ther (Heidelb)Cedirian S +7 more
europepmc +1 more source
Pim1 Serves as a Therapeutic Target for Inflammatory Arthritis via Mitochondrial Metabolism and Th17 Cell Differentiation. [PDF]
Research (Wash D C)Su Z +13 more
europepmc +1 more source
Th,-e mechanistic insights into the application of retinoids and possible adjunct therapeutic treatment to androgenic alopecia. [PDF]
Ann Med Surg (Lond)Irfan H +4 more
europepmc +1 more source
Dutasteride Infusion in Male Androgenetic Alopecia Using a Novel Drug Delivery Technique: MMP<sup>®</sup>. [PDF]
Skin Appendage DisordGasques L +5 more
europepmc +1 more source